NAUT:NASDAQNautilus Biotechnology, Inc. Analysis

Nautilus Biotechnology is trading at $2.36, just above its $2.30 support level, while technical indicators show a bearish MACD and a neutral‑to‑slightly oversold RSI at 38. Volatility is extreme, with a 30‑day swing above 80% and a beta well above 1**, indicating sharp price swings.*
The company remains a development‑stage biotech with zero revenue, negative EBITDA of $62.5M, and persistent cash burn reflected in negative operating and free cash flow. However, it holds $95.9M in cash against $28.9M of debt, giving it a modest cash runway, and recent news cites reduced operating expenses and progress toward commercializing its proteomics platform.
Valuation metrics such as a price‑to‑book of 2.07 and a forward PE of –3.18 contrast sharply with the industry’s average PE of 27, suggesting the stock is priced for future growth rather than current earnings. The upside potential is estimated near 70%, but the lack of revenue and high sector/regulatory risk keep the investment profile speculative.